Madrigal Pharmaceuticals Q3 2024 Earnings Report $327.87 -9.40 (-2.79%) As of 03/28/2025 04:00 PM Eastern Earnings HistoryForecast Madrigal Pharmaceuticals EPS ResultsActual EPS-$4.92Consensus EPS -$6.94Beat/MissBeat by +$2.02One Year Ago EPS-$5.34Madrigal Pharmaceuticals Revenue ResultsActual Revenue$62.18 millionExpected Revenue$34.60 millionBeat/MissBeat by +$27.58 millionYoY Revenue GrowthN/AMadrigal Pharmaceuticals Announcement DetailsQuarterQ3 2024Date10/31/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptMDGL Earnings History Remove Ads Madrigal Pharmaceuticals Earnings HeadlinesIs Madrigal Pharmaceuticals (MDGL) The Most Expensive Stock Insiders Are Dumping In March?March 28 at 7:40 PM | insidermonkey.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $378.44 Average PT from BrokeragesMarch 26, 2025 | americanbankingnews.comWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Oracle"—known for spotting Apple, Amazon, and Google early—has identified a firm with patented tech that could become essential to every major AI player. He shares the name and ticker in this free video—but warns the opportunity could vanish once it hits the mainstream.March 30, 2025 | InvestorPlace (Ad)Madrigal Pharmaceuticals (MDGL): Among the Best Biotech Stocks to Buy According to BillionairesMarch 18, 2025 | msn.comMadrigal Pharmaceuticals’ SWOT analysis: Rezdiffra success drives stock potentialMarch 14, 2025 | investing.comMadrigal Pharmaceuticals Announces Changes to Board of DirectorsMarch 13, 2025 | msn.comSee More Madrigal Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Madrigal Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Madrigal Pharmaceuticals and other key companies, straight to your email. Email Address About Madrigal PharmaceuticalsMadrigal Pharmaceuticals (NASDAQ:MDGL), a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.View Madrigal Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
